Meta-Analysis: GnRH Analog Preserves Ovarian Function in Early Breast Cancer

Article
Conference|San Antonio Breast Cancer Symposium (SABCS)

This video reviews a meta-analysis that looked at five studies testing the use of a gonadotropin-releasing hormone (GnRH) analog to protect ovarian function and preserve fertility in premenopausal women undergoing chemotherapy for early-stage breast cancer.

In this video, Halle C. F. Moore, MD, of the Cleveland Clinic in Ohio, discusses a meta-analysis that looked at five studies testing the use of a gonadotropin-releasing hormone (GnRH) analog to protect ovarian function and preserve fertility in premenopausal women undergoing chemotherapy for early-stage breast cancer.

Moore was one of the authors of the study (abstract GS4-01), which was presented last week at the 2017 San Antonio Breast Cancer Symposium (SABCS), held December 5–9 in San Antonio, Texas.

Recent Videos
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Using bispecific antibodies before or after CAR T-cell therapy in multiple myeloma is an area of education for community oncologists.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
Optimal cancer survivorship care may entail collaboration between a treating oncologist and a cancer survivorship expert.
Related Content
ctDNA Positivity More Frequent Less Than 6 Months from Treatment in TNBC

ctDNA Positivity More Frequent Less Than 6 Months from Treatment in TNBC

Spencer Feldman
December 20th 2024
Article

The phase 3 ZEST trial discovered that, with low ctDNA at baseline, the recurrence-free interval is longer for patients with triple-negative breast cancer.

Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

Ensuring Holistic, Individualized Transitions of Care for Cancer Survivors

Andrew M. Evens, DO, MBA, MSc
December 9th 2024
Podcast

Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

Bezuclastinib Demonstrates Improved Symptoms in Systemic Mastocytosis

Bezuclastinib Demonstrates Improved Symptoms in Systemic Mastocytosis

Darlene Dobkowski, MA
December 16th 2024
Article

Median duration on bezuclastinib was 56 weeks vs 40 weeks for placebo in non-advanced systemic mastocytosis, the phase 2 Summit trial reported.

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Exploring New Possibilities in Kidney Cancer Detection and Therapy

Karl Semaan, MD, MSc ;Neil J. Shah, MBBS;Bradley McGregor, MD
July 22nd 2024
Podcast

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

ctDNA at Baseline Linked With Larger Tumor Size and Residual Cancer Burden

ctDNA at Baseline Linked With Larger Tumor Size and Residual Cancer Burden

Ashley Chan
December 14th 2024
Article

Ultra-sensitive ctDNA testing identified ctDNA at baseline in patients with HR–positive breast cancer, results from the PELOPS trial showed.

From 2013 to 2022, the rate of important identified risks associated with ponatinib in the treatment of those with ALL or CML had decreased.

Ponatinib-Related Toxicity Management in ALL/CML Improves Over Time

Jonah Feldman
December 14th 2024
Article

From 2013 to 2022, the rate of important identified risks associated with ponatinib in the treatment of those with ALL or CML had decreased.